- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03489369
Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
2021년 2월 1일 업데이트: Symphogen A/S
A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This is the first study to test Sym022 in humans.
The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
연구 개요
상세 설명
This study will evaluate the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym022, an anti-lymphocyte activation gene 3 (anti-LAG-3) monoclonal antibody (mAb).
The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym022 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient cohorts with locally advanced/ unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.
If an MTD is not identified, a maximum administered dose (MAD) will be determined.
Sym022 will be given to patients in escalating dose cohorts; each patient will be given one fixed dose level.
연구 유형
중재적
등록 (실제)
15
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 이상 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Male or female patients, ≥ 18 years of age at the time of obtaining informed consent.
- Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
- Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.
- Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
- Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
- Not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.
Exclusion Criteria:
- Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of contraception.
- Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
- Hematologic malignancies other than lymphomas.
- Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
- Active uncontrolled bleeding or a known bleeding diathesis
- Clinically significant cardiovascular disease or condition
- Significant pulmonary disease or condition
- Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.
- An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.
- History of organ transplantation (e.g. stem cell or solid organ transplant)
- History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy
- Patients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.
- Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
- Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- Other Inhibitors of LAG-3
- Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to first administration of study drug and during study
- Any other investigational treatments within 4 weeks prior to and during study
- Radiotherapy for target lesions within 4 weeks prior to first administration of study drug unless PD has been documented in the lesion following treatment, and during study.
- Radiotherapy for non-target lesions within 1 week prior to first administration of study drug
- Immunosuppressive or systemic hormonal therapy
- Prophylactic use of hematopoietic growth factors within 1 week prior to first administration of study drug and during Cycle 1 of study
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: Sym022
Sym022 will be administered at up to 4 planned dose levels.
|
Sym022는 LAG-3에 결합하고 LAG-3/MHC-II(major histocompatibility complex class II) 상호 작용을 차단하여 T 세포 증식 및 사이토카인 생성을 증가시키는 재조합 완전 인간 항체입니다.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Assessment of Treatment Related Adverse Events (AEs).
기간: 19 months
|
Assess the safety, tolerability and dose-limiting toxicities of Sym022 on a Q2W schedule to establish the MTD and/or RP2D.
|
19 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Evaluation of the Immunogenicity of Sym022.
기간: 19 months
|
Serum sampling and incidence (%) per dose level to assess the potential for anti-drug antibody (ADA) formation.
Count of participants show the number of participants who were tested positive for anti-Sym022 ADA.
|
19 months
|
Evaluation of Objective Response (OR) or Stable Disease (SD).
기간: 13 months
|
Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), Response Evaluation Criteria in Lymphomas 2017 (RECIL 2017), or Immunotherapeutics Response Evaluation Criteria in Solid Tumors (iRECIST), depending on tumor type.
The numbers shown below correspond to the values related to RECIST v1.1.
|
13 months
|
Time to Progression (TTP) of Disease.
기간: 13 months
|
Based on time of enrollment to first evidence of progression on imaging studies, as assessed by RECIST v1.1, RECIL 2017, or iRECIST, depending on tumor type.
The numbers shown below correspond to the values related to RECIST v1.1.
|
13 months
|
Area Under the Concentration-time Curve in a Dosing Interval (AUC).
기간: 19 months
|
Will be estimated using non-compartmental methods and actual timepoints.
|
19 months
|
Maximum Concentration (Cmax)
기간: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Will be derived from observed data.
|
0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Time to Reach Maximum Concentration (Tmax)
기간: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Will be derived from observed data.
|
0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Trough Concentration (Ctrough)
기간: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Will be derived from observed data.
|
0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Terminal Elimination Half-life (T½)
기간: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Will be estimated using non-compartmental methods and actual timepoints.
|
0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Clearance (CL)
기간: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
Will be estimated using non-compartmental methods and actual timepoints.
|
0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
수사관
- 수석 연구원: Lillian Siu, MD, FRCPC, Princess Margaret Cancer Centre
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (실제)
2018년 5월 8일
기본 완료 (실제)
2020년 1월 6일
연구 완료 (실제)
2020년 1월 6일
연구 등록 날짜
최초 제출
2018년 3월 26일
QC 기준을 충족하는 최초 제출
2018년 4월 3일
처음 게시됨 (실제)
2018년 4월 5일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2021년 2월 18일
QC 기준을 충족하는 마지막 업데이트 제출
2021년 2월 1일
마지막으로 확인됨
2021년 2월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .